Clinical Trial

Early Versus Late Adjunctive Vasopressin in Septic Shock

Study acronym: CASPER-Pilot
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2026 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of the CASPER-Pilot study is to develop clinical decision support (CDS) technology within Epic to randomize patients with septic shock to early versus standard of care vasopressin initiation. The primary aim of this study will be to test the hypothesis that CDS technology can be utilized to create two distinct cohorts of patients reflecting different times of vasopressin initiation based on norepinephrine dose requirements. Secondarily, this study will evaluate the proportion of patients whose norepinephrine dose at the time of vasopressin initiation is within the specified range for the intervention arm they were randomized to. Other outcomes of evaluation will include adherence to the developed CDS technology and comparison of clinical outcomes between the two treatment arms.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-26; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2025-07-07
Trial Details
NCT Number NCT06709573
Lead Sponsor The Cleveland Clinic
Conditions Sepsis, Septic Shock
Enrollment 300 participants
Start Date 2025-04-29
Primary Completion 2026-05-01 (estimated)
Study Completion 2026-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-12